Journal
EMBO REPORTS
Volume 19, Issue 12, Pages -Publisher
WILEY
DOI: 10.15252/embr.201846935
Keywords
cancer; cGAS; immune therapy; oncolytic virus; STING
Categories
Funding
- Academia Sinica [CDA-105-L01]
- Ministry of Science and Technology [105-2311-B-001-055-MY3]
Ask authors/readers for more resources
The cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway mediates anti-microbial innate immunity by inducing the production of type I interferons (IFNs) and inflammatory cytokines upon recognition of microbial DNA. Recent studies reveal that self-DNA from tumors and by-products of genomic instability also activates the cGAS-STING pathway and either promotes or inhibits tumor development. This has led to the development of cancer therapeutics using STING agonists alone and in combination with conventional cancer treatment or immune checkpoint targeting. On the other hand, for cancers lacking the cGAS-STING pathway and thus a regular innate immunity response, oncolytic virus therapy has been shown to have therapeutic potential. We here review and discuss the dichotomous roles of the cGAS-STING pathway in cancer development and therapeutic approaches.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available